HRTX HERON THERAPEUTICS, INC. /DE/
Company Analysis
Latest News
Heron Therapeutics Enters Multi-Product Development and License Agreement with Long Grove Pharmaceuticals
Heron Therapeutics, Inc. (HRTX) has entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals, LLC, effective September...
🟢 Heron Therapeutics is trading 5.5% up with no clear catalyst identified
Heron Therapeutics is trading at $0.31, up 5.52%, with no clear company-specific catalyst identified for September 29, 2026. - The available news search...
🟢 Heron Therapeutics is trading 10.33% up today
Heron Therapeutics is trading 10.33% up at $0.30 after rebounding from its September 21, 2026 close of $0.27, with no new company-specific announcement or...
🟢 Heron Therapeutics is trading 5% up today after September 21's 12.82% decline
Heron Therapeutics is trading 5.11% up at $0.28 after rebounding from the September 21, 2026 close of $0.27, when shares fell 12.82%. - No new...
🟢 Heron Therapeutics is trading 7.41% up in pre-market with no clear catalyst identified
Heron Therapeutics is trading 7.41% up now at $0.29, with no clear company-specific announcement or fresh catalyst explaining the rebound after falling 12.82%...
🔴 Heron Therapeutics is trading 15.08% down today as immediate trigger remains unclear
Heron Therapeutics is trading 15.08% down at $0.26, despite broad U.S. markets moving higher on September 21, 2026; no new company-specific announcement...
🔴 Heron Therapeutics is trading 8.01% down today with no new company-specific catalyst identified
Heron Therapeutics is trading 8.01% down at $0.28, with no clear company-specific announcement identified for September 21, 2026. - Recent reporting points to...
🔴 Heron Therapeutics is trading 5.63% down today amid generic CINVANTI entry uncertainty
Heron Therapeutics is trading 5.63% down at $0.33, amid recent competitive pressure and uncertainty surrounding potential generic CINVANTI entry. - No major...
🟢 Heron Therapeutics is trading 5.39% up today amid low-priced-stock momentum
Heron Therapeutics is trading at $0.35, up +5.39%, with the gain appearing to reflect low-priced-stock volatility and momentum after the prior session’s +5.47%...
🟢 Heron Therapeutics is trading 5.47% up in pre-market with no clear company-specific catalyst identified
Heron Therapeutics is trading 5.47% up at $0.33 in pre-market, with no clear company-specific catalyst identified for September 3, 2026. - Latest available...
🟢 Heron Therapeutics is trading 5.45% up today amid broader risk-on sentiment
Heron Therapeutics is trading 5.45% up at $0.33, as broader risk-on sentiment supports the move despite no fresh company-specific announcement identified for...
🔴 Heron Therapeutics is trading 5.66% down today — no fresh company-specific announcement identified
Heron Therapeutics is trading 5.66% down at $0.30, with no fresh company-specific announcement identified for August 26, 2026. - Its latest material company...
🟢 Heron Therapeutics rises 5.2% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Heron Therapeutics rises 5.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Heron Therapeutics is trading 5.2% down today after revenue miss and guidance withdrawal
Heron Therapeutics is trading 5.2% down at $0.30, following recent pressure after second-quarter revenue missed expectations and management withdrew full-year...
🔴 Heron Therapeutics is trading 7.13% down today with no fresh company-specific catalyst identified
Heron Therapeutics is trading at $0.31 (-7.13%) now, with no fresh company-specific catalyst directly explaining the August 17, 2026 decline identified. • The...
🟢 Heron Therapeutics is trading 6.5% up in pre-market after extending Tax Benefit Preservation Plan through 2029
Heron Therapeutics is trading at $0.36, up +6.47% in pre-market after amending its Tax Benefit Preservation Plan. - The plan is designed to preserve the...
Heron Therapeutics Extends Tax Benefit Preservation Plan to August 2029
Heron Therapeutics, Inc. has amended its Tax Benefit Preservation Plan, effectively extending its expiration date by three years. The plan, which acts as a...
🔴 Heron Therapeutics is trading 5.5% down today after guidance withdrawal and CINVANTI patent uncertainty
Heron Therapeutics is trading 5.51% down now at $0.32 after investors continued assessing the August 10 earnings miss and withdrawal of full-year 2026...
🟢 Heron Therapeutics is trading 10.93% up today rebounding after post-earnings decline
Heron Therapeutics is trading 10.93% up at $0.36, rebounding as broader risk-on sentiment appears to support the move. - Shares closed at $0.32 on August 11,...